TP53 ‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14421 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Dong Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Connecticut, Farmington, Connecticut, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Mutation, Blast Crisis. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Patients with TP53 mutations in acute myeloid leukemia (AML) and blast phase myeloproliferative neoplasms (MPN‐BP) experience similar poor clinical outcomes. A retrospective analysis of 39 patients with TP53 mutations (23 with AML and 16 with MPN‐BP) revealed comparable mutation patterns associated with prognostic significance. A total of 47 distinct TP53 mutations were identified, including seven patients with multiple mutations. Based on clinical outcomes, we propose a two‐tiered risk stratification for TP53 ‐mutated AML and MPN‐BP. The high‐risk group mutations, such as splice site variants in Intron 4 (especially c.376), missense mutations in Exon 5 (notably p.R175H), and mutations in the oligomerization domain (OD), were associated with, particularly, worse overall survival (OS < 3 months). Conversely, single missense mutations in Exons 6 and 7 (notably p.Y220C, p.R248N, p.R248Q, and p.R248W), and mutations in the transactivation domain (TAD), constituted a low‐risk group and were associated with relatively better prognosis (median OS: 10.15 months for the low‐risk group vs. 1.3 months for the high‐risk group, p < 0.0001). These findings support the hypothesis that distinct TP53 mutations can lead to varying cellular effects, therapeutic responses, and clinical outcomes. Consequently, acute myeloid neoplasms (AML and MPN‐BP) harboring certain TP53 mutations may exhibit increased aggressiveness compared to other TP53 mutants, underscoring the need for prioritized clinical research and therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Connecticut, Farmington, Connecticut, USA.
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Dong Chen, Miguel Cantu, Alexa Siddon
Zitieren
APA
Chen, D., Cantu, M., Siddon, A., & Weinberg, O. K. (2025). TP53 ‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis. European Journal of Haematology. https://doi.org/10.1111/ejh.14421
Vancouver
Chen D, Cantu M, Siddon A, Weinberg OK. TP53 ‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis. European Journal of Haematology. 2025. doi:10.1111/ejh.14421
BibTeX
@article{Chen2025,
author = {Chen, Dong and Cantu, Miguel and Siddon, Alexa and Weinberg, Olga K},
title = {TP53 ‐Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14421}
}
EUVIMED